Plain-English translation of NCT06829459 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study compares two treatment approaches for people with advanced non-small cell lung cancer whose previous targeted therapy (called EGFR inhibitors) is no longer working. One group will take combined with — two oral medications taken by mouth daily. The other group will receive standard chemotherapy drugs given through an IV infusion. The study wants to see which approach helps patients live longer and with fewer side effects.
When patients take EGFR inhibitor drugs for lung cancer, their cancer eventually stops responding to the treatment. A specific genetic change called MET amplification may explain why this happens in some patients. This trial tests whether targeting MET with the new medication combination could help patients whose first-line treatment has stopped working.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to the new medication group, you will take two pills by mouth once daily (each day) in a fasting state (before eating). If assigned to chemotherapy, you will receive IV infusions on the first day of each 3-week cycle for up to 4 cycles, then continue with maintenance treatment if your cancer does not progress. Both groups will have regular imaging scans and blood tests to monitor how well the treatment is working, and treatment will continue until your cancer progresses, you experience unbearable side effects, or you choose to stop.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China